Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on July 17, 2025. The filing discloses a strategic development and commercialization agreement entered into on the same date with Samsung Bioepis Co., Ltd. ("Samsung").
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, or debt levels for the reporting period. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreement Details
The primary material event is the agreement with Samsung regarding the transition of commercial rights for two products back to Samsung, which will then supply Harrow for U.S. commercialization:
- Products: BYOOVIZ® (ranibizumab-nuna) and OPUVIZTM (aflibercept-yszy).
- Roles: Samsung will develop, manufacture, and supply the products; Harrow will commercialize them in the U.S. market.
- Financial Terms:
- Harrow will make a one-time upfront payment to Samsung.
- Samsung is eligible for additional one-time payments based on net sales milestones.
- Harrow will pay Samsung a share of net sales generated in the U.S. market.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the agreement terms. The text notes that the agreement follows the completion of a transition of commercial rights from Biogen back to Samsung.
Investor Verification Checklist
- Verify the exact amount of the one-time upfront payment to Samsung, which is not disclosed in this filing.
- Confirm the specific percentage or formula for the "share of net sales" payable to Samsung.
- Review the attached Press Release (Exhibit 99) for detailed milestone thresholds and payment triggers.
- Assess the impact of this supply agreement on Harrow's gross margins compared to prior arrangements with Biogen.